Global Pericarditis Market Segments 2024, Forecast To 2033
5 Mar, 2024
The pericarditis market has shown strong growth, increasing from $2.17 billion in 2023 to $2.35 billion in 2024, with a compound annual growth rate (CAGR) of 8.4%. This growth is attributed to increased prevalence of cardiovascular diseases and aging population. Looking ahead to 2028, the market is expected to reach $3.2 billion, maintaining an 8.1% CAGR. The forecasted growth is linked to increased focus on precision medicine, regulatory support for orphan drugs, and patient advocacy.
Global Pericarditis Market Key Driver
The pericarditis market is poised for growth due to the rising prevalence of cardiovascular diseases. Cardiovascular conditions pose significant health risks, with one heart attack occurring every 40 seconds in the US. Approximately 805,000 Americans experience heart attacks annually, emphasizing the need for pericarditis treatment. The market thrives on addressing the cardiovascular disease surge.
Get A Free Sample Of The Global Pericarditis Market ReportGlobal Pericarditis Market Segments
The pericarditis market covered in this report is segmented –
1) By Type: Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis
2) By Diagnosis And Treatment: Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (Ct), X-Ray, Medication, Surgical Treatment
3) By Application: Hospitals And Clinics, Medical Institutes, Ambulatory Surgical Centers, Research Organizations
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the pericarditis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the pericarditis market report during the forecast period. The regions covered in the pericarditis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Pericarditis Industry Players
Pfizer Inc.; AstraZeneca plc; Allergan plc; Merck & Co. Inc.; Bayer AG; Reckitt Benckiser Group plc; PerkinElmer Inc.; Novartis International AG; Sanofi S.A.; Johnson & Johnson Services Inc.; Takeda Pharmaceutical Co. Ltd.; Zydus Cadila Healthcare Ltd.; Sun Pharmaceutical Ltd.; Regeneron Pharmaceuticals Inc.; Kiniksa Pharmaceuticals Ltd.; R-Pharm International LLC; Unimed Laboratories; Teva Pharmaceutical Industries Ltd.; Swedish Orphan Biovitrum AB; Cigna Group; Hikma pharmaceutical plc; Wockhardt Ltd.; XYMAS Pharmaceutical; Sakura Finetek USA Inc.; Hitachi High-Technologies Corporation; Leica Biosystems Nussloch GmbH; Euromex Microscopen BV; Celestron LLC; Labomed Inc.; Olympus Corporation; Bruker Corporation
Get The Full Global Pericarditis Market Report
AIOps Pericarditis Market Overview
Pericarditis refers to inflammation and irritation of the thin, saclike tissue called pericardium that is surrounding the heart. The common symptom is chest pain, which is caused when sac layers are rubbing against the heart and inflamed.
Pericarditis Global Market Report 2023 provides data on the global pericarditis market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The pericarditis market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.